Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Woo-Jin | - |
dc.contributor.author | Lee, Soon-Tae | - |
dc.contributor.author | Byun, Jung-Ick | - |
dc.contributor.author | Sunwoo, Jun-Sang | - |
dc.contributor.author | Kim, Tae-Joon | - |
dc.contributor.author | Lim, Jung-Ah | - |
dc.contributor.author | Moon, Jangsup | - |
dc.contributor.author | Lee, Han Sang | - |
dc.contributor.author | Shin, Yong-Won | - |
dc.contributor.author | Lee, Keon-Joo | - |
dc.contributor.author | Kim, Soyun | - |
dc.contributor.author | Jung, Keun-Hwa | - |
dc.contributor.author | Jung, Ki-Young | - |
dc.contributor.author | Chu, Kon | - |
dc.contributor.author | Lee, Sang Kun | - |
dc.date.accessioned | 2021-08-11T17:44:23Z | - |
dc.date.available | 2021-08-11T17:44:23Z | - |
dc.date.issued | 2016-05-03 | - |
dc.identifier.issn | 0028-3878 | - |
dc.identifier.issn | 1526-632X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9118 | - |
dc.description.abstract | Objective: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment. Methods: We recruited 80 patients with ALE who were treated with rituximab as a second-line immunotherapy from the Korea Autoimmune Synaptic and Paraneoplastic Encephalitis Registry and reviewed 81 patients without rituximab as a control. We grouped patients according to the detection or type of antibodies; in addition, we evaluated clinical, laboratory, first-line immunotherapy, and rituximab treatment profiles and defined main outcomes as improvements on the modified Rankin Scale (mRS) score and a favorable mRS score (0-2) at the last follow-up. Results: Functional improvement occurred more frequently in the rituximab group compared to the control group. In the rituximab group, 30 (37.5%) patients had synaptic autoantibodies, 15 (18.8%) in the paraneoplastic autoantibodies, and 35 (43.8%) were antibody-negative. The effect of rituximab was the same regardless of autoantibody status. Additional monthly rituximab therapy and partial response to first-line immunotherapies were associated with mRS score improvements, as well as favorable mRS scores. mRS scores of 4-6 as the worst neurologic status predicted an unfavorable mRS score. There were no reported serious infusion-related or infectious adverse effects of rituximab. Conclusions: Rituximab is effective and safe as a second-line immunotherapy for ALE, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab. Classification of evidence: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1212/WNL.0000000000002635 | - |
dc.identifier.scopusid | 2-s2.0-84966508579 | - |
dc.identifier.wosid | 000377202100011 | - |
dc.identifier.bibliographicCitation | Neurology, v.86, no.18, pp 1683 - 1691 | - |
dc.citation.title | Neurology | - |
dc.citation.volume | 86 | - |
dc.citation.number | 18 | - |
dc.citation.startPage | 1683 | - |
dc.citation.endPage | 1691 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | ASPARTATE RECEPTOR ENCEPHALITIS | - |
dc.subject.keywordPlus | ANCA-ASSOCIATED VASCULITIS | - |
dc.subject.keywordPlus | CLINICAL-MANIFESTATIONS | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | CYCLOPHOSPHAMIDE | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Autoimmune limbic encephalitis | - |
dc.subject.keywordAuthor | Rituximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.